Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEA-TGT (SGN-TGT) Phase 1 in Advanced Malignancies
NCT04254107Phase 1Terminated
- Sponsor
- Seagen Inc.
- Start
- May 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of SEA-TGT in non-small cell lung cancer (NSCLC), Gastric carcinoma (GC), gastroesophageal junction carcinoma (GEJ) and 9 more (3 arms), sponsored by Seagen Inc. Primary endpoints: Number of participants with adverse events (AEs) up to 3 years, Number of participants with laboratory abnormalities by grade up to 3 years and 1 more. Started May 2020; status: terminated.
02
Drugs
SEA-TGT
03
Conditions
non-small cell lung cancer (NSCLC)Gastric carcinoma (GC)gastroesophageal junction carcinoma (GEJ)classical Hodgkin lymphoma (cHL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04254107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04254107.